Pancreatic Cancer Research

ResearcherShire (Switzerland)No recent work listed

Floris A. de Jong

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5069985668. Sources: OpenAlex.

Their work

Papers
7 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
17
Papers, trials and grants by year

2016: 1 paper · 2017: 1 paper · 2018: none · 2019: 4 papers · 2020: none · 2021: 1 paper

Papers 7

  1. Early dose reduction/delay and the efficacy of liposomal irinotecan with fluorouracil and leucovorin in metastatic pancreatic ductal adenocarcinoma (mPDAC): A … Co-author DOI 10.1016/j.pan.2020.10.029↗
  2. Quality of life in metastatic pancreatic cancer patients receiving liposomal irinotecan plus 5-fluorouracil and leucovorin. Co-author DOI 10.1016/j.ejca.2018.09.029↗
  3. NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors. Co-author DOI 10.1016/j.ejca.2018.12.007↗
  4. Liposomal irinotecan and 5-fluorouracil/leucovorin in older patients with metastatic pancreatic cancer - A subgroup analysis of the pivotal NAPOLI-1 trial. Last author DOI 10.1016/j.jgo.2019.02.011↗
  5. Nomogram for Predicting Survival in Patients Treated with Liposomal Irinotecan Plus Fluorouracil and Leucovorin in Metastatic Pancreatic Cancer. Co-author DOI 10.3390/cancers11081068↗
  6. Quality-adjusted survival with combination nal-IRI+5-FU/LV vs 5-FU/LV alone in metastatic pancreatic cancer patients previously treated with gemcitabine-based … Co-author DOI 10.1038/bjc.2017.67↗
  7. Post-gemcitabine therapy for patients with advanced pancreatic cancer - A comparative review of randomized trials evaluating oxaliplatin- and/or irinotecan-con… Co-author DOI 10.1016/j.ctrv.2016.09.001↗

Closest collaborators

The 17 strongest of 17 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Li‐Tzong Chen · 6 shared papers, 2017–2021 · strength 0.59
  2. Jens Thomas Siveke · 6 shared papers, 2017–2021 · strength 0.59
  3. Jean‐Frédéric Blanc · 6 shared papers, 2016–2021 · strength 0.54
  4. Bruce Belanger · 4 shared papers, 2019–2021 · strength 0.43
  5. Andrea Wang‐Gillam · 4 shared papers, 2017–2019 · strength 0.35
  6. Teresa Mercade Macarulla · 3 shared papers, 2019–2021 · strength 0.34
  7. Richard A Hubner · 4 shared papers, 2016–2019 · strength 0.30
  8. Daniel D. Von Hoff · 3 shared papers, 2017–2019 · strength 0.24
  9. Tanios Bekaii‐Saab · 2 shared papers, 2019–2021 · strength 0.24
  10. Davide Melisi · 2 shared papers, 2017–2019 · strength 0.14
  11. Antonio Cubillo · 2 shared papers, 2017–2019 · strength 0.14
  12. Marc F Botteman · 1 shared paper, 2017 · strength 0.06
  13. Uwe Pelzer · 1 shared paper, 2017 · strength 0.06
  14. Fortunato Ciardiello · 1 shared paper, 2016 · strength 0.06
  15. Arndt Vogel · 1 shared paper, 2016 · strength 0.06
  16. Sharlene Gill · 1 shared paper, 2016 · strength 0.06
  17. Alfredo Carrato · 1 shared paper, 2016 · strength 0.06

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.